HCM
JAZZ icon

Highbridge Capital Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

Highbridge Capital Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-1,500
Closed -$221K – 1274
2014
Q2 		$221K Sell
1,500
-100
-6% -$13.9K ﹤0.01% 950
2014
Q1 		$222K Buy
+1,600
New +$241K ﹤0.01% 938

Other funds holding JAZZ

PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
SIG
Senator Investment Group New York $2.18B AUM 58.56% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Highbridge Capital Management's JAZZ Position: Q3 2017 in Review

Highbridge Capital Management sold out of Jazz Pharmaceuticals (JAZZ) in Q3 2017, closing a stake of 32,245 shares — an estimated $5.01M sold.

Highbridge Capital Management first reported a position in JAZZ in Q1 2014 and held it in 7 quarters. The position peaked at $5.01M in Q2 2017. 303 funds tracked by Wall St. Rank hold JAZZ as of Q3 2017.

  • Highbridge Capital Management reported no remaining Jazz Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
  • Highbridge Capital Management sold 32,245 Jazz Pharmaceuticals shares in Q3 2017, an estimated $5.01M.
  • Highbridge Capital Management first reported a position in Jazz Pharmaceuticals in Q1 2014 and held it in 7 quarters.
  • Highbridge Capital Management's Jazz Pharmaceuticals position peaked at $5.01M in Q2 2017.
  • 303 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q3 2017.

Based on Highbridge Capital Management's 13F filing for Q3 2017, filed 14 Nov 2017.